We purified from porcine pancreas a hypocalcemic peptide clearly distinguishable from other pancreatic osteotropic factors such as amylin, calcitonin, and glucagon. Porcine pancreas was processed by acetone extraction, anion exchange chromatography, isoelectric focusing, and reverse-phase high performance liquid chromatography. Fractions were assayed for their inhibitory effects on bone resorption in vitro. Amino acid sequence of a homogeneous 28-kDa protein revealed 92% homology to a human elastase IIIB in the N terminus. Recombinant human elastase IIIB (rhEIIIB) inhibited bone resorption in organ culture stimulated by 1,25-dihydroxyvitamin D 3 at concentrations as low as 75 ng/ ml. Antibodies to rhEIIIB recognized purified pancreatic factor in Western blots and blocked its inhibitory effect on bone resorption. This antiresorptive activity was abolished by phenylmethylsulfonyl fluoride, suggesting the importance of elastase proteolytic activity for inhibition of bone resorption. In vivo, rhEIIIB and purified pancreatic factor significantly decreased recombinant human interleukin-1␣-induced hypercalcemia. In conclusion, a novel naturally occurring inhibitor of bone resorption and calcium-lowering peptide has been identified in porcine pancreas. Because this pancreatic peptide has systemic effects on bone resorption and blood ionized calcium at low concentrations, it may represent a physiological regulator of normal bone remodeling and calcium homeostasis.
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Recently, we have found that systemic administration of extracts of the porcine pancreas (PPE) 1 that have been prepared according to the methods described by Takaoka et al. (1) reproducibly decrease blood ionized calcium (Ca 2ϩ ) concentrations in normal mice and inhibit bone resorption, which is stimulated by parathyroid hormone (PTH), interleukin-1␣, prostaglandin E 2 , tumor necrosis factor, transforming growth factor ␣, and 1,25-dihydroxyvitamin D 3 (1,25D 3 ) in organ cultures of fetal rat long bones (2) . Inhibition of bone resorption by PPE was associated with inhibition of osteoclast formation (3). Furthermore, PPE, which was partially purified by anion exchange and size exclusion column chromatography, diminished hypercalcemia and osteoclastic bone resorption in athymic nude mice bearing a human squamous cancer (4) .
In the present study, we have purified the bone resorption inhibitory activity in the PPE to homogeneity. We have found that this peptide shares about 90% amino acid homology with a serine protease in the elastase family (pancreatic elastase IIIB isozyme). Both native pancreatic and rhEIIIB inhibited bone resorption and lowered blood ionized calcium in a dosedependent manner. Antibodies to rhEIIIB recognized native pancreatic and rhEIIIB in Western blots and neutralized bone resorption inhibitory activity of both. These data suggest that the pancreas also might play a role as a bone/calcium metabolism-regulating organ by the production of peptides with proteolytic activity.
EXPERIMENTAL PROCEDURES
Purification of PPE-Initial steps of the purification were described earlier (2, 3) . Crude PPE was run through a DE-52 column (Whatman Labsales) (4.8 ϫ 60 cm, Kontes) equilibrated with 0.1 M Tris-HCl, pH 7.5. Protein was eluted by stepwise washes with 0.1, 0.2, and 1 M NaCl at a flow rate of 120 ml/h. Active fractions were pooled, dialyzed against 0.1 M Tris-HCl, pH 7.5, and rechromatographed on DEAE-Sephacel column (Pharmacia Biotech Inc.) (4.8 ϫ 10 cm, Kontes). Active fractions were subjected to isoelectrofocusing in ampholytes, pH 3-10 (Miniphor, Rainin). Biologically active fractions were chromatographed on C 18 reverse-phase high performance liquid chromatography (HPLC) Vydac column (2.1 mm ϫ 15 cm) (Rainin) in a gradient of 0 -70% acetonitrile in 0.1% trifluoroacetic acid at a flow rate of 0.15 ml/min. Amino acid sequence of the HPLC purified protein was obtained from automated Edman degradation using an Applied Biosystems model 477 protein sequencer.
Biological Assays in Culture and Measurements of Proteolytic Activity-Proliferation stimulating activity was assessed by the incorporation of [ 3 H]thymidine using human osteoblastic osteosarcoma MG-63 cells. Cells (5 ϫ 10 3 /well) were cultured in flat bottom 96-well plates in ␣ minimum essential medium (Hazleton Biologics, Inc.) supplemented with 0.2% bovine serum albumin (Sigma) in the presence of serially diluted (1:2) fractionated PPE for 44 h. Cells were then incubated with 0.2 Ci/well [ 3 H]thymidine (ICN Radiochemicals Inc.) for a further 4 h. At the end of the incubation, cells were detached by treatment with trypsin-EDTA solution (Life Technologies, Inc.) and harvested onto glass fiber strips using a multiple automated cell harvester (Cambridge Technology Inc.). The radioactivity was measured by liquid scintillation counting.
Proteolytic activity of PPE and rhEIIIB was assessed by hydrolysis of 1 mM N-succinyl-Ala-Ala-Pro-Leu-p-nitroanilide (SAPL) (Sigma) in 50 mM Tris-HCl, pH 7.5, and monitoring the absorbance changes at 405 nm.
Assays for Bone Resorption and for Bone Formation-Bone resorption was assessed by determining 45 Ca release from fetal rat long bones in organ culture as described (4, 5) . Bones were cultured for 120 h in the medium supplemented with 1 mg/ml bovine serum albumin and fractionated PPE. Medium was collected at 48 and 120 h. Bone resorption was assessed as the percentage of total 45 Ca that was released into the medium.
Osteoclast-like cell formation was assessed by counting tartrateresistant acid phosphatase-positive multinucleated cell (TRAP(ϩ)) number in murine marrow cultures according to the method previously described (6, 7) . TRAP is a widely accepted histochemical marker of mouse osteoclasts (8) . Bone marrow cells harvested from 4 -6-week-old male C57BL mice (Harlan) were inoculated onto 24-well plates (2 ϫ 10 6 cells/0.5 ml/well) and cultured in ␣ minimum essential medium supplemented with 10% fetal calf serum in the presence of 10 Ϫ8 M 1,25D 3 (Biomol Research Laboratories, Inc.) and fractionated PPE for 6 days. The cultures were washed in phosphate-buffered saline, fixed in 60% acetone in citrate buffer, pH 5.4, air dried, and stained for TRAP using a commercial kit (Sigma). All TRAP(ϩ) multinucleated cells (cells stained in red with more than three nuclei) were counted manually under light microscopy.
Isolated rat osteoclasts were prepared from the femora and tibiae of newborn rats according to techniques previously described (6, 7) . The bones of each rat were curetted with a scalpel blade into 1 ml of medium and vigorously agitated with a pipette. The cell suspension was added to slices of sperm whale dentine. The cells were then incubated for 15 min at 37°C to allow osteoclasts to attach to the surface of dentine. Dentine slices were then removed, washed to remove nonadherent cells, and placed in separate wells containing 100 l of ␣ minimum essential medium supplemented with 10% fetal calf serum. The wells were incubated in the absence or the presence of 20 ng/ml synthetic human PTH-rP peptide 1-34 (Peninsula Laboratories Inc.) for 24 h in humidified air (10% CO 2 ) at 37°C before quantification of osteoclast numbers and assessment of resorption pits as described (9) .
A single experiment (n ϭ 3-6) used 16 -20 slices with a minimum of 3-4 slices/treatment. For examination of resorption lacunae, the slices were sonicated in 0.1 M NaOH and stained with 0.1% (w/v) toluidine blue (Sigma). Resorption pits were counted using light microscopy, and the plan area of matrix resorbed was quantitated using a computerassisted JAVA (Jandel Scientific).
Assay for Hypocalcemic Activity in Mice-ICR Swiss mice (male, 6 -8 weeks old, Harlan) were given 0.1 g of rhIL-1␣ (a generous gift of Dr. Richard Chizzonite, Hoffmann-La Roche, Nutley, NJ) in 10 l of phosphate-buffered saline subcutaneously on calvaria four times a day to induce hypercalcemia as described previously (10) . 30 min after each rhIL-1␣ injection, purified native PPE (1 mg) or rhEIIIB (10 g) was injected at the same site of calvaria. Blood Ca 2ϩ was determined before the injections of PPE as described (2, 3) .
rhEIIIB, Antibodies, and Immunoblotting-rhEIIIB and polyclonal neutralizing antibodies to rhEIIIB were kindly provided by Dr. Ito, Sankyo Pharmaceutical Co. (Tokyo, Japan). Rabbit antisera against purified native PPE were also raised and IgG fractions were purified using E-Z-Sep kit (Pharmacia Biotech Inc.).
Purified PPE was subjected to SDS-polyacrylamide gel electrophoresis on 10 -15% gradient gel using PHAST System (Pharmacia Biotech Inc.). The gels were transblotted to ProBlott nitrocellulose membrane (Applied Biosystems, Foster City, CA) in CAPS. The membranes were immunostained with the anti-PPE antibodies.
RESULTS
We used two different in vitro assays successively to monitor the biological activities of PPE. First, fractionated materials were tested for effects on DNA synthesis in human MG-63 osteoblastic osteosarcoma cells. These cells exhibit similar responses to those of primary fetal calvarial cells to growth regulatory peptides. The active fractions were then assayed for bone resorption inhibitory activity in organ cultures of fetal rat long bones. Our aim was to identify the activity that has the capacities to stimulate osteoblast proliferation and inhibit bone resorption.
PPE was purified to homogeneity by successive steps including anion exchange chromatography on DE-52 and DEAESephacel, isoelectric focusing, and reverse-phase HPLC on C 18 column. On anion exchange columns, the biological activity that promoted MG-63 proliferation and inhibited 1,25D 3 -stimulated bone resorption was eluted with 0.2 M NaCl (Fig. 1) . On isoelectric focusing, the activity was detected at an isoelectric point of 4.3-4.5 (Fig. 2) . The PPE was eluted as a single peak at a position of 48% acetonitrile on the C 18 reverse-phase HPLC column (Fig. 3A) . Table I summarizes the results of purification of PPE. The purified activity, further referred to as PX, promoted proliferation of MG-63 cells and inhibited 1,25D 3 -stimulated bone resorption (Fig. 3B) as well as the resorption stimulated by PTH and IL-1 (data not shown). This material migrated as a single band at 28 kDa on SDS-polyacrylamide gel electrophoresis (Fig. 4) .
N-terminal amino acid sequencing of the 28-kDa protein was performed, and 32 amino acids from the N terminus were obtained (Fig. 5) . The sequence was found to have 92% homology with the sequence of human elastase IIIB reported previously (11) .
The purified PPE was subjected to Western blotting using the antibodies raised against to rhEIIIB. As shown in Fig. 4 , the purified PPE was recognized at 28 kDa by the antibodies to rhEIIIB. Furthermore, the antibodies raised against the purified native PPE also reacted with rhEIIIB on Western blotting showing a distinct band at 28 kDa. These results demonstrate that the purified PPE is immunologically identical to rhEIIIB. rhEIIIB at doses ranging from 75 to 7,500 ng/ml markedly inhibited 1,25D 3 -stimulated bone resorption in organ cultures of fetal rat long bones (Fig. 6A) and mouse calvaria (Fig. 6B) . The bone resorption inhibitory effect of the purified PPE and rhEIIIB was completely blocked by polyclonal antibodies to 
FIG. 2. Activity and pH profile of pancreatic extract after isoelectrofocusing.
After isoelectrofocusing in a pH range of 3-10, aliquots of fractions were used in fetal rat long bone assay measuring 1,25D 3 -stimulated bone resorption. Ϫ, no additions; ϩ, 1,25D 3 alone. rhEIIIB (Fig. 7) . Calcitonin, a known inhibitor of bone resorption, also decreased 1,25D 3 -stimulated bone resorption. However, the calcitonin effect was not neutralized by the antibodies to rhEIIIB. In addition, the purified PPE as well as rhEIIIB inhibited resorption pit formation by isolated rat osteoclasts ( Fig. 8 ) and decreased osteoclast-like cell formation (TRAP) in mouse marrow cultures (Fig. 9) . These effects were also blocked by the antibodies to rhEIIIB (data not shown). We tested rhEI and other serine proteases (␣-chymotrypsin, plasmin) for bone resorption inhibitory activity and found that rhEI and other proteases were 50-fold less potent than rhEIIIB. These data indicate that purified PPE is functionally indistinguishable from rhEIIIB.
Purified PPE and rhEIIIB hydrolyzed chromogenic elastase substrate, SAPL. Both preparations showed the K m values for SAPL of 160 Ϯ 50 M. Treatment of rhEIIIB (75 ng) with 1 mM phenylmethylsulfonyl fluoride, which is a specific serine protease inhibitor, for 1 h at 4°C followed by extensive dialysis abolished the proteolytic activity toward SAPL and bone resorption inhibitory activity of rhEIIIB and the purified PPE (Fig. 10) . This suggests that the biological activity of rhEIIIB and purified PPE is due to proteolytic activity and the serine residue at the active site is necessary for exhibition of bone resorption inhibitory activity.
We next determined whether rhEIIIB decreased blood Ca 2ϩ in mice. Hypercalcemia was induced in mice by repeated subcutaneous calvarial injections of rhIL-1␣ (0.1 g/injection, four injections/day). Subcutaneous administration of purified native PPE (1 mg/injection, four injections/day) over the calvaria 30 min after each rhIL-1␣ injection significantly decreased blood Ca 2ϩ in a similar manner to that seen by the rhEIIIB (10 g/injection, four injections/day) (Fig. 11) . To confirm that a decrease in blood Ca 2ϩ is not due to proteolytic degradation by rhEIIIB, we determined the molecular size of rhIL-1␣, which was treated with rhEIIIB (1 g/ml) for 2 h by Western blotting. rhIL-1␣ remained intact after 2 h of treatment with rhEIIIB (data not shown).
DISCUSSION
In this report, we describe the isolation and characterization of a novel pancreatic peptide factor. We show that this peptide reduces hypercalcemia in vivo and in vitro inhibits osteoclastic bone resorption and stimulates proliferation of osteoblast-like MG-63 cells. The amino acid sequence reveals it to be closely related to the family of elastase-like serine proteases. This protein had been identified previously as elastase IIIB (11) . No specific enzyme activity was described for this protein. How- a One unit is defined as the activity of human recombinant elastase IIIB at a concentration of 100 ng/ml in a fetal rat long bone assay measuring 1,25D 3 -stimulated 45 Ca release. ND, not determined. ever, related proteins have been shown to have similar biological effects. We have previously shown that partially purified preparations of porcine pancreatic extracts lower whole blood ionized calcium in vivo and inhibit osteoclastic bone resorption in vitro (2, 3, 4) . Moreover, caldecrin, another member of the elastase family, has been shown to inhibit bone resorption in vitro (12, 13) . There are significant differences between PX and caldecrin. Caldecrin bone resorption inhibitory activity is not affected by phenylmethylsulfonyl fluoride, whereas PX requires proteolytic activity for bone resorption. Unlike PX, caldecrin inhibits only PTH-stimulated bone resorption but not 1,25D 3 -or IL-1-stimulated 45 Ca release. Thus, the differences between these two elastases may be more profound.
If the activity of PX depends on enzymatic cleavage of a substrate, then identification of this substrate is of great importance to the biological activity. Although we do not know the identity of the putative substrate, there are several possibilities. Elastase-like serine proteases have recently been found to generate the soluble mature form of transforming growth factor ␣ (14, 15) . It is possible that proteolytic cleavage by elastases of membrane-bound cytokines and growth factors might change local levels of soluble cytokines and growth factors in the bone microenvironment, which in turn may modulate proliferation or differentiation of bone cells. In support of this hypothesis, data that demonstrate the effects of soluble forms of receptors to peptide cytokines and growth factors on a variety of cells have been accumulating (16) , and it has been reported that serine proteases alter integrin-mediated cell attachment to substrates (17) . One intriguing possibility is that PX may be related to adipsin, the serine protease that has been linked to adipocyte differentiation. Adipsin has greater amino acid homology at the substrate binding site with elastase IIIB FIG. 6 . Activity of recombinant human elastase IIIB in fetal organ culture assays. 1,25D 3 -stimulated 45 Ca release was measured in the presence of indicated concentrations of hEIIIB in fetal rat long bone (A) or mouse calvaria (B) assays.
FIG. 7.
Neutralizing effect of antibodies on biological activity of PX and recombinant human elastase IIIB in fetal organ culture assay. 1,25D 3 -stimulated 45 Ca release from fetal rat long bones was measured in the presence of PX (120 ng/ml), hEIIIB (50 ng/ml), or calcitonin (CT, 100 milliunits/ml) in the presence or the absence of rabbit polyclonal antibody against recombinant elastase IIIB.
FIG. 8.
Effect of hEIIIB on isolated osteoclasts. Rat osteoclasts were plated on sperm whale dentin in the presence and the absence of 1,25D 3 (10 Ϫ10 M) and hEIIIB (750 and 75 ng/ml). The area and number of pits per slice were quantitated using a computer-assisted JAVA.
than any other member of the serine protease family (18) .
The pancreas has long been linked to calcium homeostasis. Glucagon, calcitonin, and amylin all have inhibitory effects on osteoclasts (19 -21) . Pancreatic carcinoma is sometimes associated with hypercalcemia, presumably related to PTH-rP overproduction (22) . More importantly and possibly more relevant to the current report, acute pancreatitis is often associated with hypocalcemia (23) . Acute pancreatitis is invariably associated with increased serum concentrations of pancreatic enzymes. It is possible that release of elastase IIIB may be a contributory factor in the etiology of the hypocalcemia of acute pancreatitis.
Our evidence thus far suggests that we have identified a protein that lowers plasma calcium in vivo, inhibits osteoclastic bone resorption, and stimulates proliferation of osteoblastic cells. Its effects on calcium homeostasis and bone resorption are reminiscent of those of calcitonin. However, its proliferative effects on osteoblastic cells suggest that it may also influence bone formation. Thus, determining both the physiological role as well as its potential as a therapeutic agent for common bone diseases is a major priority in future studies on this protein. Hypercalcemia was induced in mice by injections of interleukin 1 (IL-1) (400 ng), followed by no further treatment (control) or injections with 10 g each of PX or hEIIIB. Blood samples were withdrawn at indicated times for measurements of ionized calcium levels.
